REGISTER
MedJ at JSCO 2025 with Dr. Norikazu Masuda
MedJ at JSCO 2025 with Dr. Norikazu Masuda is presented here as a key issue in JSCO. By organizing evidence on JSCO, HR, ADC, it turns scattered results into practical conclusions for clinicians and patients.

Norikazu Masuda, Kyoto University, Japan

Confronting core challenges in HR+ advanced breast cancer!

The treatment goal is no longer "eradication," but optimal sequencing of ADC and endocrine therapies to maximize survival while reducing patient burden.

0
0
Loading